Zhejiang Hisun Pharmaceutical has filed a patent for a pyrimidine derivative represented by formula (I) as a therapeutic agent, specifically as a FGFR4 kinase inhibitor. The method claims treating diseases of FGF19 amplification by administering the compound. GlobalData’s report on Zhejiang Hisun Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

According to GlobalData’s company profile on Zhejiang Hisun Pharmaceutical, Cancer treatment biomarkers was a key innovation area identified from patents. Zhejiang Hisun Pharmaceutical's grant share as of January 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.

Fgfr4 kinase inhibitor for treating fgf19 amplification diseases

Source: United States Patent and Trademark Office (USPTO). Credit: Zhejiang Hisun Pharmaceutical Co Ltd

A patent application (Publication Number: US20240018130A1) discloses a method for treating diseases associated with FGF19 amplification by administering a compound represented by formula (I) or its derivatives to a patient in need of treatment. The compound can also be a specific compound of formula (II) with defined substituents R1, R2, and R3, where R1 can be halogen or alkoxy, R2 is —NHC(O)CH-CH2, and R3 is a monospiroheterocyclyl optionally substituted by various groups like alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, and heteroaryl.

The method further specifies the possible combinations of R1, R2, and R3, providing a range of options for the compound used in the treatment. This patent application aims to address diseases related to FGF19 amplification by utilizing specific compounds and their derivatives, potentially offering a targeted approach to managing these conditions. The detailed description of the compounds and their variations in the claims highlights the specificity and customization possible in the treatment method, potentially leading to more effective and tailored therapeutic interventions for patients with FGF19 amplification-related diseases.

To know more about GlobalData’s detailed insights on Zhejiang Hisun Pharmaceutical, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies